BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
January 10 2024 - 3:00PM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”),
a global clinical-stage biopharmaceutical company focused on using
a groundbreaking technology platform for drug discovery and
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs, today announced that on
January 4, 2024, it received a Foreign Delinquency Compliance Plan
Alert Letter (the “Letter”) from The Nasdaq Stock Market LLC
(“Nasdaq”). In the Letter, the staff of Nasdaq notified the Company
that it is not in compliance with Nasdaq Listing Rule 5250(c)(2),
because it has not timely filed its Form 6-K for the period ended
June 30, 2023 (the “Filing”).
In accordance with Nasdaq Listing Rules, the
Company has 60 calendar days to submit a plan to regain compliance.
If Nasdaq accepts the Company’s plan, Nasdaq can grant the Company
an exception of up to 180 calendar days from the Filing’s due date,
or until July 1, 2024, to regain compliance.
The Letter has no immediate effect on the
listing or trading of the Company’s ordinary shares on Nasdaq. The
Company’s management is working diligently to complete the Filing
as soon as practicably possible to regain compliance with the
Nasdaq Listing Rule 5250(c)(2).
About BeyondSpringBeyondSpring
(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company
focused on developing innovative therapies to improve clinical
outcomes for patients with high unmet medical needs. The Company is
advancing its first-in-class lead asset, Plinabulin, as a direct
anti-cancer agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform and has an
initial R&D collaboration with Eli Lilly. Learn more by
visiting https://beyondspringpharma.com.
Investor
Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Historical Stock Chart
From Sep 2024 to Oct 2024
BeyondSpring (NASDAQ:BYSI)
Historical Stock Chart
From Oct 2023 to Oct 2024